A drug maker heavily criticized for high prices saw a sharp drop in sales at the end of last year, prompting it to cut sales staff.
Gilead Sciences reported Tuesday that its earnings fell 33 percent in the fourth quarter of 2016 from the year before. A major reason for the drop is a sharp decline in sales of its hepatitis C cures Harvoni, which plunged 51 percent, and Sovaldi, which dropped an even bigger 65 percent.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.